Thermo Fisher Scientific Inc., known for its steady performance and low volatility, remains a strong long-term investment option. On July 16, the company announced an expansion of its strategic collaboration with Sanofi, aimed at boosting drug product manufacturing capabilities in the United States.
As part of this initiative, Thermo Fisher will acquire Sanofi’s manufacturing facility located in Ridgefield, New Jersey. The site, a cutting-edge sterile fill-finish and packaging center employing over 200 people, will continue producing Sanofi’s therapy portfolio while also supporting Thermo Fisher’s growing network of biopharma and biotech customers seeking domestic manufacturing solutions.
This acquisition reflects rising demand for U.S.-based production capacity amid growing emphasis on supply chain resilience and pharmaceutical independence. Following the transaction’s completion, the Ridgefield site will become an integral part of Thermo Fisher’s expansive global operations.
Thermo Fisher offers a broad portfolio of products and services, including analytical instruments, lab equipment, reagents, software, and diagnostics. Its operations span four key segments: Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Diagnostics.
While Thermo Fisher continues to deliver consistent returns and stable dividends in a growing market, some analysts suggest that select AI-focused stocks may currently offer higher short-term upside potential, especially amid shifting trade policies and the U.S. onshoring trend. For investors seeking high-growth opportunities, AI sector plays could complement a long-term position in established names like TMO.